MDM2 and non-small cell lung carcinoma: Bioinformatic analysis based on TCGA data indicated that MDM2 was highly expressed in TP53 wild‐type compared with TP53 mutant NSCLC (including lung adenocarcinoma and lung squamous cell carcinoma), suggesting overexpression of MDM2 could be beneficial for the growth of TP53 wild‐type cancer (Figure 1G).